Cite
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
MLA
Gay, Cynthia L., et al. “Stable Latent HIV Infection and Low-Level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.” Journal of Infectious Diseases, vol. 225, no. 5, Mar. 2022, pp. 856–61. EBSCOhost, https://doi.org/10.1093/infdis/jiab487.
APA
Gay, C. L., James, K. S., Tuyishime, M., Falcinelli, S. D., Joseph, S. B., Moeser, M. J., Allard, B., Kirchherr, J. L., Clohosey, M., Raines, S. L. M., Montefiori, D. C., Shen, X., Gorelick, R. J., Gama, L., McDermott, A. B., Koup, R. A., Mascola, J. R., Floris-Moore, M., Kuruc, J. D., & Ferrari, G. (2022). Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. Journal of Infectious Diseases, 225(5), 856–861. https://doi.org/10.1093/infdis/jiab487
Chicago
Gay, Cynthia L, Katherine S James, Marina Tuyishime, Shane D Falcinelli, Sarah B Joseph, Matthew J Moeser, Brigitte Allard, et al. 2022. “Stable Latent HIV Infection and Low-Level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.” Journal of Infectious Diseases 225 (5): 856–61. doi:10.1093/infdis/jiab487.